These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 24851018)

  • 1. Preoperative selective desensitization of live donor liver transplant recipients considering the degree of T lymphocyte cross-match titer, model for end-stage liver disease score, and graft liver volume.
    Hong G; Yi NJ; Suh SW; Yoo T; Kim H; Park MS; Choi Y; Lee K; Lee KW; Park MH; Suh KS
    J Korean Med Sci; 2014 May; 29(5):640-7. PubMed ID: 24851018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lessons learnt from living donor liver transplantation with ABO-incompatibility: A single-centre experience from southern India.
    Shajahan S; Sasidharan ST; Surendran S; Shenoy V; Padma UD
    Indian J Gastroenterol; 2019 Feb; 38(1):23-28. PubMed ID: 30848450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of desensitization methods: Rituximab with/without plasmapheresis in ABO-incompatible living donor liver transplantation.
    Lee EC; Kim SH; Shim JR; Park SJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):119-125. PubMed ID: 29576278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desensitization protocol for highly sensitized renal transplant patients: a single-center experience.
    Kute VB; Vanikar AV; Trivedi HL; Shah PR; Goplani KR; Patel HV; Gumber MR; Patel RD; Kanodia KV; Suthar KS; Trivedi VB; Modi PR
    Saudi J Kidney Dis Transpl; 2011 Jul; 22(4):662-9. PubMed ID: 21743208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of rituximab desensitization on blood-type-incompatible adult living donor liver transplantation: a Japanese multicenter study.
    Egawa H; Teramukai S; Haga H; Tanabe M; Mori A; Ikegami T; Kawagishi N; Ohdan H; Kasahara M; Umeshita K
    Am J Transplant; 2014 Jan; 14(1):102-14. PubMed ID: 24279828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of desensitization in human leukocyte antigen- and ABO-incompatible living donor kidney transplantation: a single-center experience in more than 100 patients.
    Al Meshari K; Pall A; Chaballout A; El Gamal H; Al Mana H; Humaidan H; Alzayer F; Al Talhi M
    Transplant Proc; 2013 May; 45(4):1423-6. PubMed ID: 23726587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biliary stricture is the only concern in ABO-incompatible adult living donor liver transplantation in the rituximab era.
    Song GW; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Jung DH; Park GC; Kang SH; Jung BH; Yoon YI; Kim N
    J Hepatol; 2014 Sep; 61(3):575-82. PubMed ID: 24801413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
    Becker LE; Siebert D; Süsal C; Opelz G; Leo A; Waldherr R; Macher-Goeppinger S; Schemmer P; Schaefer SM; Klein K; Beimler J; Zeier M; Schwenger V; Morath C
    Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Outcomes of ABO-incompatible Pediatric Living Donor Liver Transplantation.
    Honda M; Sugawara Y; Kadohisa M; Shimata K; Sakisaka M; Yoshii D; Uto K; Hayashida S; Ohya Y; Yamamoto H; Yamamoto H; Inomata Y; Hibi T
    Transplantation; 2018 Oct; 102(10):1702-1709. PubMed ID: 29620615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Section 15. A desensitizing protocol without local graft infusion therapy and splenectomy is a safe and effective method in ABO-incompatible adult LDLT.
    Song GW; Lee SG; Hwang S; Ahn CS; Kim KH; Moon DB; Ha TY; Jung DH; Park GC; Park HW; Park YH; Kang SH; Jung BH
    Transplantation; 2014 Apr; 97 Suppl 8():S59-66. PubMed ID: 24849837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of Desensitization Therapy in Immunologically High-Risk Kidney Transplantation: Single-Center Experience.
    Sinangil A; Ucar ZA; Koc Y; Barlas S; Abouzahir S; Ecder ST; Akin EB
    Transplant Proc; 2019 Sep; 51(7):2268-2273. PubMed ID: 31358450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desensitization with the Use of an Antibody Removal-Free Protocol in ABO-Incompatible Kidney Transplant Recipients with a Low Anti-A/B Antibody Titer.
    Nanmoku K; Shinzato T; Kubo T; Shimizu T; Kimura T; Yagisawa T
    Transplant Proc; 2018 May; 50(4):982-986. PubMed ID: 29731097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ABO-Incompatible Living Donor Liver Transplantation with Reduced Rituximab Dose: A Retrospective Analysis of 65 Patients - Can We Fast-Track Liver Transplant Surgery and Improve Long-Term Survival?
    Hsu SC; Thorat A; Jeng LB; Li PC; Chen TH; Yang HR; Poon KS
    Ann Transplant; 2020 Sep; 25():e923502. PubMed ID: 32943600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ABO-incompatible living donor liver transplantation is suitable in patients without ABO-matched donor.
    Kim JM; Kwon CH; Joh JW; Kang ES; Park JB; Lee JH; Kim SJ; Paik SW; Lee SK; Kim DW
    J Hepatol; 2013 Dec; 59(6):1215-22. PubMed ID: 23928408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for antibody-mediated rejection in ABO blood-type incompatible and donor-specific antibody-positive liver transplantation.
    Tajima T; Hata K; Haga H; Kusakabe J; Kageyama S; Yurugi K; Hishida R; Zhao X; Nishikori M; Nagao M; Takaori-Kondo A; Uemoto S; Hatano E
    Liver Transpl; 2023 Jul; 29(7):711-723. PubMed ID: 36749821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of desensitization protocol with and without rituximab in sensitized kidney transplant recipients.
    Green H; Nesher E; Aizner S; Israeli M; Klein T; Zakai H; Rahamimov R; Rozen-Zvi B; Mor E
    Clin Transplant; 2019 Jun; 33(6):e13562. PubMed ID: 30941818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrepancy of B cell frequency between periphery and spleen after rituximab treatment in ABO-incompatible liver transplantation.
    Iso Y; Sawada T; Kita J; Shiraki T; Sakuraoka Y; Kato M; Shimoda M; Kubota K
    Hepatogastroenterology; 2013 Oct; 60(127):1624-6. PubMed ID: 24634932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-Center Experience of ABO-Incompatible Living-Donor Liver Transplantation With a New Simplified Intravenous Immunoglobulin Protocol: A Propensity Score-Matching Analysis.
    Kim JD; Choi DL; Kim SG; Lee AJ
    Transplant Proc; 2016 May; 48(4):1134-8. PubMed ID: 27320573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ABO-Incompatible Adult Living Donor Liver Transplantation Under the Desensitization Protocol With Rituximab.
    Song GW; Lee SG; Hwang S; Kim KH; Ahn CS; Moon DB; Ha TY; Jung DH; Park GC; Kim WJ; Sin MH; Yoon YI; Kang WH; Kim SH; Tak EY
    Am J Transplant; 2016 Jan; 16(1):157-70. PubMed ID: 26372830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.